|1.||Olivares, A: 1 article (03/2014)|
|2.||Ibáñez, M: 1 article (03/2014)|
|3.||Pineda, S: 1 article (03/2014)|
|4.||Anzola, B: 1 article (03/2014)|
|5.||Sasaki, Masayuki: 1 article (02/2011)|
|6.||Aoki, Yoko: 1 article (02/2011)|
|7.||Aizaki, Koichi: 1 article (02/2011)|
|8.||Saito, Yoshiaki: 1 article (02/2011)|
|9.||Matsubara, Yoichi: 1 article (02/2011)|
|10.||Sugai, Kenji: 1 article (02/2011)|
|2.||Drug Hypersensitivity (Drug Allergy)
02/01/2001 - "In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion."
02/01/2001 - "The purpose of this study was to detect drug allergy to chlorazepate or a metabolite in vitro by means of the lymphocyte transformation test (LTT), and to determine the concentrations of the T-helper (Th) 2-type cytokine interleukin (IL)-5 and the Th1-type cytokine interferon (IFN) -gamma in the culture supernatants. "
12/03/1999 - "Dipotassium clorazepate suppressed amygdaloid-kindled seizures at 2 and 5 mg/kg, while 1 mg/kg or more suppressed hippocampal-kindled seizures. "
12/03/1999 - "The contralateral cortical after-discharge duration in the dipotassium clorazepate-treated group was significantly shorter than the after-discharge duration in the amygdala in the first seven stimulations, whereas it was significantly shorter only in the first three stimulations in the control group, indicating that dipotassium clorazepate suppressed the spread of seizure activity from focus to contralateral cortex. "
12/03/1999 - "Effect of dipotassium clorazepate on amygdaloid-kindling and comparison between amygdaloid- and hippocampal-kindled seizures in rats."
08/01/1998 - "Dipotassium clorazepate at doses of 1 mg/kg or more produced an anticonvulsant effect, but did not readily suppress limbic seizures. "
08/01/1998 - "Dipotassium clorazepate was administered intraperitoneally in rats that showed two stable stage 5 seizures induced at the GST current intensity. "
|4.||Body Weight (Weight, Body)
12/01/1990 - "Clorazepate dipotassium was administered orally to 8 healthy dogs at a dosage of 2 mg/kg of body weight, q 12 h, for 21 days. "
01/01/1995 - "Dosages were: clorazepate dipotassium: body weight < 55 kg: 10 mg; body weight > 55 kg: 20 mg; nordiazepam: 1 gtt/kg; 5 mg = 24 gtt). "
06/01/1980 - "Five pregnant Long-Evans rats were given 32 mg/kg of body weight of clorazepate dipotassium (Tranxene) intramuscularly on gestational days 8.5, 9.5, and 10.5. "
06/01/1980 - "Clorazepate dipotassium (Tranxene), an anticonvulsant benzodiazepine, was tested for teratogenicity by injecting ten pregnant Long-Evans rats with 32 mg/kg of body weight intramuscularly on days 8.5, 9.5, and 10.5 of gestation. "
07/29/1974 - "Clorazepate dipotassium in the treatment of intractable epilepsy."
12/03/1999 - "We examined the effect of dipotassium clorazepate (7-chloro-1, 3-dihydro-2-oxo-5-phenyl-1H-1, 4-benzodiazepine-3-carboxylate potassium hydroxide), an antianxiety drug, on amygdaloid kindling and compared its effects for 7 successive days on amygdaloid- versus hippocampal-kindled seizures, using the rat kindling model of epilepsy. "
01/01/1983 - "Clonazepam, chlorazepate, nitrazepam and clobazam are also prescribed as chronic treatment of various forms of epilepsy. "
|4.||Clorazepate Dipotassium (Tranxene)
|4.||Renal Dialysis (Hemodialysis)